ADCs are formed by conjugating monoclonal antibodies (mAb) and small-molecule drugs through linkers. The specificity of mAb to tumor cells allows small-molecule drugs to target tumor tissues, effectively reducing the high toxicity of traditional small-molecule drugs and improving overall treatment efficiency. Learn more about our ADC contract manufacturingcapabilities.
Recent Sightings
No recent sighting activity.
We use cookies to offer you a better browsing experience, analyze site traffic, and personalize content. Read about how we use cookies and how you can control them in our Privacy Policy. If you continue to use this site, you consent to our use of cookies.
